Rom J Ophthalmol:Alport综合征中罕见的前后两侧晶状体病变病例

2018-12-24 MedSci MedSci原创

印度Gajra Raja医学院眼科的Tiwari US和Aishwarya A等人近日在Rom J Ophthalmol杂志上发表了一项病例报告,他们报告了一例Alport综合征中罕见的双侧前后晶状体突变病例,并对该病例进行了细致的描述。

印度Gajra Raja医学院眼科的Tiwari US和Aishwarya A等人近日在Rom J Ophthalmol杂志上发表了一项病例报告,他们报告了一例Alport综合征中罕见的双侧前后晶状体突变病例,并对该病例进行了细致的描述。

Alport综合征是一种遗传性疾病,其特征是听力丧失、进行性肾功能衰竭和眼前段异常,包括前晶状体和角膜混浊、白内障、黄斑视网膜病变和颞部视网膜变薄等。在这种综合征的同一只眼中,出现前、后两侧晶状体病变是一种罕见的发现,只有少数这样的报道。

在这篇病例报告中,他们报告了一例22岁男性患者,患有前后双侧晶状体病变,并伴随感觉神经性耳聋和肾炎,最终诊断为Alport综合征。

原文出处:

Tiwari, U.S., A. Aishwarya, and R. Kujur, Bilateral combined anterior and posterior lenticonus in Alport's Syndrome. Rom J Ophthalmol, 2018. 62(3): p. 228-230.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2019-01-02 仁医06
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2019-01-30 jiekemin
  3. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-26 syscxl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1954070, encodeId=b85d19540e0a5, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Wed Jan 02 08:00:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036005, encodeId=524120360055e, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Wed Jan 30 01:00:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431402, encodeId=79cb14314021d, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458428, encodeId=35a5145842818, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467389, encodeId=044d146e3898f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541418, encodeId=36d715414181c, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Dec 26 13:00:00 CST 2018, time=2018-12-26, status=1, ipAttribution=)]

相关资讯

Alport 综合征诊断和治疗专家推荐意见

Alport 综合征(Alport syndrome)亦称遗传性进行性肾炎,临床特点是血尿、蛋白尿及进行性肾功能减退,部分患者可合并感音神经性耳聋、眼部异常、食管平滑肌瘤等肾外表现。该病由编码肾小球基底膜Ⅳ型胶原α3~α5链的基因COL4An(n=3,4,5)基因突变所致。约85%的Alport 综合征患者是COL4A5 或COL4A5 和COL4A6 两个基因突变导致的X 连锁显性遗传型Alpo

Retina:视网膜剥离手术引起内界膜剥离后与Alport综合征相似

名古屋大学医学研究科眼科的Fukukita H近日在Retina上发表了一篇有趣的文章。视网膜的最内层基底膜,也就是内界膜(ILM),有时会在玻璃体手术中被剥离。他们探究了ILM丢失后对视网膜的影响。

Kidney int:Alport综合征的足细胞损伤进程

足细胞受损是促进肾小球疾病进展的常见机制之一。由足细胞产生的α3α4α5(IV)胶原异源三聚体缺陷引起的Alport综合征肾小球病与尿液中可检测到的足细胞脱离率增高以及肾小球足细胞数量减少有关,这表明有缺陷的足细胞粘附于肾小球基底膜可能在疾病的进展中发挥重要作用。近期,一项发表在杂志Kidney int上的研究使用95名受试者【尿研究】和41份存档的活组织检查【活组织检查】的Alport综合征的遗

Alport综合征患者早期使用ACEI有益

    Alport综合征患者最终不可避免的发展为终末期肾病,而且目前没有好的治疗可以改善这一状况。       这里我们观察三个家族性Alport综合征患者使用ACEI治疗后是否可以延缓患者至透析治疗的时间以及改善患者的期望值。这些患者按照肾功能情况进行分类,其中33名合并血尿或者微量白蛋白尿、115名蛋白尿、26名肾功能受损和109名未治疗